

Israel's ProSpecBio launches Activin-A recombinant protein for brain injury research

October 13, 2025 | News

Expanding ProSpecBio's cytokine-related product line



Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell–derived recombinant Activin-A, now available for immediate delivery worldwide.

Activin-A is increasingly recognised as a potential therapeutic agent for conditions such as brain injury and inflammatory diseases. Studies have shown that it can help reduce damage and inflammation, making it a vital tool for researchers exploring new treatments and breakthroughs in these critical areas.

With its CHO cell–derived purity and reliability, ProSpecBio's Activin-A recombinant protein provides laboratories and academic institutions with the quality and consistency required for groundbreaking research. This product expands ProSpecBio's cytokine-related product line, reinforcing its position as a trusted partner to researchers globally.

“By introducing recombinant Activin-A into our portfolio, we aim to accelerate discoveries in neuroscience, immunology, and regenerative medicine,” said Nadav Amaran, Managing Director at ProSpecBio.